1 hr ago | The Motley Fool
Attention, Investors: It's Time to Sell
The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics around the investing world.
5 hrs ago | Local Tech Wire
Human Genome Science shareholder sues over 'poison pill' vs. GSK
Not all Human Genome Science shareholders agree with the company position that GlaxoSmithKline's $2.6 billion purchase offer is insufficient.
9 hrs ago | Drugs.com
GSK Announces Start of Phase III Programme for Combination of...
GSK Announces Start of Phase III Programme for Combination of Dabrafenib and Trametinib in BRAF V600 Mutation-Positive Metastatic Cutaneous Melanoma GlaxoSmithKline plc.
13 hrs ago | BioSpace
GlaxoSmithKline Melanoma Drugs May Steal Market From Roche
HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Two experimental skin cancer drugs from GlaxoSmithKline - each designed to block different pathways used by tumour cells - look set to steal a march on Roche's pioneering ... (more)
14 hrs ago | Local Tech Wire
Reactions to GSK Aids drug help Fda understand others
GlaxoSmithKline AIDS drug abacavir holds a hidden key to understanding allergic reactions that some patients experience from other drugs.
18 hrs ago | Maktoob Business
Human Genome shareholder files case to restrain "poison pill"
The British company had intended to take its $13-a-share offer direct to investors after Human Genome's board said it was inadequate.
New Market Research Report: Soft Tissue Sarcoma Global Clinical Trials Review, H1, 2012
This report provides elemental information and data relating to the clinical trials on Soft Tissue Sarcoma.
3. Indian pharma giant eyes Nottingham
The city is the home of healthcare retailer Boots and has strong pharmacy and chemistry departments at the University of Nottingham which recently announced that GlaxoSmithKline was giving 12m for new sustainable chemistry laboratories.
GlaxoSmithKline Diabetes Drug Data Revealed Amid Hostile Takeover
GlaxoSmithKline Plc will reveal detailed results today on an experimental treatment for diabetes that's part of the reason for a $2.6 billion hostile takeover bid for Human Genome Sciences Inc.
Local News: GSK workers give charity's barge a lick of paint
It was a case of all hands on deck for the 20 GlaxoSmithKline employees when they repainted Cathja in Isleworth.
Collaboration proves to be path to acquisitions by GSK
GlaxoSmithKline may find its next acquisition target where the U.K. drugmaker found the last two: among more than a dozen companies it collaborates with to develop new treatments.
GlaxoSmithKline Amends Offer to Address Human Genome Sciences, Inc. Poison Pill
HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia GlaxoSmithKline plc Wednesday, May 23, tweaked the terms of its hostile $2.59 billion offer for Human Genome Sciences Inc.
EU Big Pharmas Such as AstraZeneca PLC, GlaxoSmithKline, Sanofi...
Drug Giants Such as AstraZeneca PLC , GlaxoSmithKline , Sanofi Join Forces With Academia on $285 Million Antibiotic Pact GlaxoSmithKline and AstraZeneca welcomed the launch of a pioneering approach to antibiotic research in Europe that will see pharmaceutical and biotechnology companies working alongside public partners to tackle the rising threat ... (more)
GlaxoSmithKline Sifts Through Collaborations for Acquisitions
GlaxoSmithKline Plc may find its next acquisition target where the U.K. drugmaker found the last two: among more than a dozen companies it collaborates with to develop new treatments.
Milestone Triggered in Connection With Filing of New Drug Application in Japan for Arzerra
COPENHAGEN, Denmark, May 24, 2012 -- Genmab A/S announced today a milestone payment of DKK 20 million from GlaxoSmithKline to Genmab in connection with the filing of the New Drug Application to the Japanese Ministry of Health, Labor and Welfare .
Healthcare Business Recap: GlaxoSmithKline Shakes on Human Genome,...
GlaxoSmithKline shares move lower Wednesday as the firm modifies the terms of its $2.6 billion tender offer for Human Genome , which require that its quarry redeem or invalidate its poison pill.
GlaxoSmithKline: The Good News Just Keeps On Coming
Just last month GlaxoSmithKline was in the news for a move to acquire Human Genome Sciences , its partner of up to twenty years for $2.6 billion.
A 'Least-Bad' Option For Foreign Developed Equity Exposure
While we usually recommend using single-country funds as satellite holdings given their niche exposure, we think iShares MSCI United Kingdom Index is suitable as a core foreign-equity holding.
Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
MALVERN, Pa., May 21, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. is raising its full year 2012 revenue guidance to a range of $293 to $315 million and is reducing its guidance for net loss to a range of $5 to $10 million.
GlaxoSmithKline to help sell Auxilium's testosterone gel
Auxilium Pharmaceuticals, Inc. and GlaxoSmithKline entered into an agreement Monday to co-promote Testim, Auxilium's testosterone replacement therapy product used in adult males.